Shay Capital’s Spero Therapeutics SPRO Stock Holding History

Shay Capital’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$160K	Buy	72,391 +2,037	+3%	+$5.33K	0.01%	418
2026 Q1	$165K	Buy	70,354 +10,065	+17%	+$23.9K	0.01%	404
2025 Q4	$140K	Sell	60,289 -3,378	-5%	-$7.84K	0.01%	436
2025 Q3	$120K	Buy	+63,667	New	+$140K	0.01%	374
2024 Q4	–	Sell	-25,000	Closed	-$33.5K	–	423
2024 Q3	$33.5K	Hold	25,000	–	–	﹤0.01%	299
2024 Q2	$32.5K	Sell	25,000 -281,967	-92%	-$425K	﹤0.01%	251
2024 Q1	$528K	Buy	+306,967	New	+$481K	0.08%	173

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Shay Capital's SPRO Position: Q2 2026 in Review

Shay Capital increased its Spero Therapeutics (SPRO) stake by 2.9% in Q2 2026, buying an estimated $5.33K and bringing the position to 72,391 shares worth $160K. The position accounts for 0.01% of the portfolio, ranked #418.

Shay Capital first reported a position in SPRO in Q1 2024 and has held it in 7 quarters since. The position peaked at $528K in Q1 2024. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Shay Capital held 72,391 shares of Spero Therapeutics worth $160K as of Q2 2026.
Shay Capital bought 2,037 Spero Therapeutics shares in Q2 2026, an estimated $5.33K.
Spero Therapeutics made up 0.01% of Shay Capital's portfolio in Q2 2026, its #418 holding.
Shay Capital first reported a position in Spero Therapeutics in Q1 2024 and has held it in 7 quarters since.
Shay Capital's Spero Therapeutics position peaked at $528K in Q1 2024.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.